|
Greg Gardiner, Ph.D. brings over 30 years of industry, consulting and investment experience to the Healthcare Group of CMM. He is also a partner in Elm Street Ventures, an early stage venture fund specializing in the life sciences, and currently serves as an advisor to Yale University's Office of Cooperative Research (OCR), as a director of five biotech companies, and as a consultant and advisor to several investment funds and pharmaceutical and biotech companies. He was formerly Managing Director of Yale's OCR, where he was responsible for development of technology and licensing of intellectual property created by Yale faculty. Prior to his tenure with Yale's OCR, Dr. Gardiner was Group Director of R&D Operations, Pfizer Central Research, where he designed and implemented Pfizer's external biotechnology strategy. At Pfizer, Dr. Gardiner managed a $150 million equity portfolio, as well as Pfizer's position in five venture capital partnerships. As part of his responsibilities, Dr. Gardiner concluded over 300 collaborative research agreements, placing $250 million in research funding with companies such as Neurogen, Incyte Pharmaceuticals, Millennium Pharmaceuticals, Scios, and OSI Pharmaceuticals. Dr. Gardiner also participated in the management of Pfizer's worldwide drug discovery program, and was responsible for the scientific evaluation of licensing candidates including Lipitor, Celebrex, and Aricept. Dr. Gardiner holds an adjunct faculty position in pharmacology at Yale University School of Medicine. He received a Ph.D. in Physical Chemistry from Fordham University and was a Sterling Fellow in Chemistry at Yale. | 